THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

04 October 2024

Graft Polymer Selects Eurofins Discovery for Pharmacology Testing in Joint Pre-Clinical Programme

Graft Polymer (UK) Plc (LON: GPL) (the "Company"), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce the selection of Eurofins Discovery ("Eurofins") to carry out initial pharmacology testing for its co-lead aminoindane series. This testing will begin immediately.

This programme is being developed under the collaboration agreement with Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF) ("Awakn"), which was first announced on 18 July 2024. The focus of this joint programme is the development of next-generation medicines targeting trauma-related mental health conditions, such as Post-Traumatic Stress Disorder ("PTSD"), a condition affecting approximately 13 million adults in the U.S. and 20 million individuals across the US, UK, and key European markets.

Eurofins Discovery, a leading global provider of drug discovery products and services, will conduct tests on Graft Polymer's co-lead aminoindane series, specifically assessing its potential for serotonin, dopamine, and noradrenaline reuptake inhibition. This phase marks a significant milestone in the programme, following the successful synthesis of the co-lead series, as announced on 28 August 2024.

Anthony Tennyson CEO of Graft Polymer, commented: "We are pleased with this development, Eurofins is an industry leader in drug discovery research. This marks an important step in our mission to bring new and innovative solutions to those suffering from trauma-related mental health disorders like PTSD. The expertise of Eurofins, combined with our collaborative approach with Awakn, puts us in an excellent position to advance this pre-clinical programme swiftly and effectively."

Professor David Nutt, Senior Scientific Advisor at Graft Polymer, added: "The aminoindane series being developed shows great promise in modulating key neurotransmitter systems involved in mental health conditions like PTSD. By targeting serotonin, dopamine, and noradrenaline reuptake, this pharmacological testing could unlock new therapeutic pathways for addressing trauma-related disorders. We look forward to seeing the outcomes of this crucial pre-clinical stage."

Enquiries:

Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director. anthonytennyson@graftpolymer.co.uk

Allenby Capital (Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

About Graft Polymer (UK) Plc

Graft Polymer (UK) Plc is an innovative biotechnology company focused on developing intellectual property relating to the treatment of mental health and substance use disorders, and the co-development of therapeutics for mental health disorders.  Our mission is to improve outcomes for individuals suffering from these conditions, with an initial focus on trauma-related mental health disorders, such as PTSD, which affects approximately 13 million adults in the U.S. and 20 million in US, UK, and key EU  markets.

For more information, please visit www.graftpolymer.co.uk.